QIAGEN (QGEN)
(Delayed Data from NYSE)
$44.85 USD
-0.08 (-0.18%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $44.86 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
QIAGEN N.V. [QGEN]
Reports for Purchase
Showing records 201 - 220 ( 236 total )
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q13 Preview - Expecting A Mixed Bag with Lighter Sales & Better EPS - Sequencing Strategy and Growing Cancer Dx Competition In Focus - Reaffirm N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q13 Recap - Ex-US HPV Tenders Help Results Edge Higher - Molecular Business Fine - Is FCF Improvement Sustainable? - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Expecting In-line 3Q13 - Looking for Better Pharma Momentum & Ok System Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Technical Analysis - Biotech Stocks Ignored and Oversold, Offering Good Entry
Provider: Drexel Hamilton, LLC
Analyst: SINE B
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Retooling Model Post 2Q13 Results - More Optimistic on 2014 Leverage Story vs Street - Not Yet Convinced on 2014 Sales - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q13 Pre-conference Call Summary - In-line Results
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Expecting In-line 2Q13 - Expecting Solid Dx System Placements & So-So Tools - Cancer Dx Acceleration Could Makes Us More Constructive
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Somewhat More Positive Following Investor Meetings - Good Tone On System Placements and TB Franchise - Maintaining NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q13 First Read - Results a Tad Soft - Solid Diagnostics Growth Offset by Challenging Academia - Guidance Trimmed Due to Sequester - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q13 Recap - Results A Bit Soft - Equipment Sales Missed Our Forecast Due to Sequester
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
1Q13 Preview - Expecting In-line Results - Eyes on Strength from Recent M&A and KRAS Momentum - Still Waiting for Sequencer Performance Specs
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Tightening Our 1Q13 Revenue Estimate Due to Greater Fx Impact and More Realistic Flu & Cold Season Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Next-Gen Sequencer Unveiled at AGBT As Planned - Emphasis on Workflow for Clinical Apps - Specs Expected Friday - Limited 2013 Revs - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q12 Recap - Solid Top-line Driven By Molecular Dx & Applied Testing.
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q12 Pre-conference Call Recap - Sales Solid Likely Due to Dx
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
4Q12 Preview - Expecting a Slight Beat Driven by Late December Disease Activity
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
3Q12 Pre-conference Call Recap - Sales In line - EPS Beats By $0.02 Due to Lower Tax Rate - Acquisitions Perform Fine - BRIC Growth Solid - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
Company: QIAGEN N.V.
Industry: Medical - Biomedical and Genetics
2Q12 Recap - Encouraging Tone Overall - Very Strong Instrument Orders Drive Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z